An Integrated Radio-immunological Approach
Launched by ISTITUTO ONCOLOGICO VENETO IRCCS · Feb 24, 2022
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a type of aggressive brain tumor called glioblastoma, which affects adults. The researchers want to understand how certain immune cells in the body, particularly those related to iron metabolism, behave in these tumors. They will use advanced MRI scans alongside tests to analyze the tumor's environment. By doing this, they hope to learn more about the immune response to these tumors and how it might be improved.
To participate in this study, patients need to be at least 18 years old and have a confirmed diagnosis of malignant glioma. They must also be able to undergo an MRI scan with a special contrast agent called gadolinium. Participants will be informed about the study and will need to sign a consent form to show they understand it is a research trial. Overall, this study aims to provide valuable insights into glioblastomas and how the immune system interacts with these tumors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients with histologic confirmation of malignant glioma
- • Patients must be age \>= 18 years
- • Patients must be able to obtain an MRI scan with gadolinium contrast
- * Patients must sign informed consent indicating that they are aware of the investigational nature of this study:
About Istituto Oncologico Veneto Irccs
Istituto Oncologico Veneto IRCCS is a leading cancer research and treatment institution located in Italy, dedicated to advancing oncological science and improving patient outcomes. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it combines clinical excellence with cutting-edge research, focusing on innovative therapies and comprehensive cancer care. The institute plays a pivotal role in the development and execution of clinical trials, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective treatment strategies. Through its commitment to high-quality research and patient-centered care, Istituto Oncologico Veneto IRCCS aims to enhance the understanding and treatment of cancer on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Florence, , Italy
Padova, , Italy
Patients applied
Trial Officials
Susanna Mandruzzato, PhD
Principal Investigator
Istituto Oncologico Veneto IOV-IRCCS
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials